Disease Markers / 2022 / Article / Tab 2 / Research Article
Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib Table 2 Associations of NLR, PLR, and their variations with clinicopathological characteristics.
Characteristics Pre-NLR Pre-PLR Post-NLR variation Post-PLR variation ≤3.41 > 3.41 ≤205.63 >205.63 Decrease Rise Decrease Rise Age (years) 0.221 0.244 0.714 0.468 <65 43 (28.3%) 48 (31.6%) 48 (31.6%) 43 (28.3%) 49 (32.2%) 42 (27.6%) 59 (38.8%) 32 (21.1%) ≥65 35 (23.0%) 26 (17.1%) 38 (25.0%) 21 (15.1%) 31 (20.4%) 30 (19.8%) 36 (23.7%) 25 (16.4%) Gender 0.871 0.121 0.293 0.512 Male 56 (36.8%) 54 (35.5%) 58 (38.2%) 52 (34.2%) 55 (36.2%) 55 (36.2%) 67 (44.1%) 43 (28.3%) Female 22 (14.5%) 20 (13.2%) 28 (18.4%) 14 (9.2%) 25 (16.4%) 17 (11.2%) 28 (18.4%) 14 (9.2%) Pathology 0.646 0.519 0.918 0.966 Adenocarcinoma 34 (22.4%) 35 (23.0%) 41 (27.0%) 28 (18.4%) 36 (23.7%) 33 (21.7%) 43 (28.3%) 26 (17.1%) Squamous carcinoma and others 44 (28.9%) 39 (25.7%) 45 (29.6%) 38 (25.0%) 44 (28.9%) 39 (25.7%) 52 (34.2%) 31 (20.4%) Performance status 0.573 0.519 0.745 0.399 0-1 58 (38.2%) 52 (34.2%) 64 (42.1%) 46 (30.3%) 57 (37.5%) 53 (34.9%) 71 (46.7%) 39 (25.7%) 2-3 20 (13.2%) 22 (14.4%) 22 (14.5%) 20 (13.1%) 23 (15.1%) 19 (12.5%) 24 (15.8%) 18 (11.8%) Driver gene EGFR/ALK/c-met 0.530 0.118 0.950 0.100 Mutant type 18 (11.8%) 14 (9.2%) 22 (14.5%) 10 (6.6%) 17 (11.2%) 15 (9.9%) 24 (15.8%) 8 (5.3%) Wild type 60 (39.5%) 60 (39.5%) 64 (42.1%) 56 (36.8%) 63 (41.4%) 57 (37.5%) 71 (46.7%) 49 (32.2%) Number of metastases 0.532 0.598 0.706 0.556 ≤3 44 (28.9%) 38 (25.0%) 48 (31.6%) 34 (22.4%) 42 (27.6%) 40 (26.3%) 53 (34.9%) 29 (19.1%) >3 34 (22.4%) 36 (23.7%) 38 (25.0%) 32 (21.1%) 38 (25.0%) 32 (21.1%) 42 (27.6%) 28 (18.4%) History of tumor surgery 0.711 0.380 0.679 0.108 No 43 (28.3%) 43 (28.3%) 46 (30.3%) 40 (26.3%) 44 (28.9%) 42 (27.6%) 49 (32.2%) 37 (24.3%) Yes 35 (23.0%) 31 (20.4%) 40 (26.3%) 26 (17.1%) 36 (23.7%) 30 (19.7%) 46 (30.3%) 20 (13.2%) Number of previous treatment lines 0.582 0.380 0.089 0.251 3 44 (28.9%) 45 (29.6%) 53 (34.9%) 36 (23.7%) 52 (34.2%) 37 (24.3%) 59 (38.8%) 30 (19.7%) >3 34 (22.4%) 29 (19.1%) 33 (21.7%) 30 (19.7%) 28 (18.4%) 35 (23.1%) 36 (23.7%) 27 (17.8%)
All the
values are obtained with chi-square.
